{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:23:32Z","timestamp":1787765012332,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Brachytherapy is the gold-standard treatment for choroidal melanoma. This study evaluated iodine-125 brachytherapy by using Ocuprosta seeds with indigenous non-collimated plaques in Asian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective single-center study in a tertiary care hospital of 12 eyes with choroidal melanoma in 12 Asian patients who underwent brachytherapy with Ocuprosta seeds fixed on non-collimated plaques and had a follow-up of at least 32 months (mean: 42.4 \u00b1 9.5 months; median: 40 months). Radiotherapy was planned after developing the digital 3D model of the tumor within the eye by using radiological images and clinical pictures. Ocuprosta iodine-125 seeds were used on indigenous non-collimated gold plaques to deliver the radiation for precalculated time. \u201cSuccessful outcome\u201d was taken as a decrease in the volume of the tumor, and \u201cunsuccessful outcome\u201d was defined as no change in the tumor volume or increase in the tumor volume at 24 months after brachytherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean decrease in tumor volume was 21% (914.5 \u00b1 912.2 mm\n                      <jats:sup>3<\/jats:sup>\n                      to 495.7 \u00b1 633.6 mm\n                      <jats:sup>3<\/jats:sup>\n                      ) after brachytherapy, which correlated with the baseline volume of the tumor. Ten eyes (83.3%) showed a reduction in tumor volume, whereas two eyes showed an increase in the volume of the tumor after brachytherapy. One of the cases with a reduction in tumor size developed neovascular glaucoma. Enucleation was done in three eyes. A globe salvage rate of 75% and tumor regression rate of 83% were seen in the present study using Ocuprosta seeds.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Iodine-125 brachytherapy with uncollimated indigenous gold plaques is an effective treatment modality for choroidal melanomas in Asian patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1694_23","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:01:50Z","timestamp":1703206910000},"page":"S90-S95","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Iodine-125 brachytherapy for choroidal melanoma by using Ocuprosta seeds with indigenous non-collimated plaques: Our initial experience"],"prefix":"10.4103","volume":"72","author":[{"given":"Subina","family":"Narang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awadesh K","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbir","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mannat","family":"Giran","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K","family":"Saxena","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Radiochemistry and Isotope Group, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Department of Radiology, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh K","family":"Walia","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K","family":"Meena","sequence":"additional","affiliation":[{"name":"CSIR-Central Scientific Instruments Organisation (CSIO), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Radiology, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Astrahan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000512738","article-title":"Uveal melanoma in Asians: A review","volume":"7","author":"Manchegowda","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: Trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2147\/OPTH.S129645","article-title":"Brachytherapy for patients with uveal melanoma: Historical perspectives and future treatment directions","volume":"12","author":"Brewington","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R5-20260508","first-page":"3","article-title":"Therapy of uveal melanoma A review","volume":"77","author":"Rusnak","year":"2021","journal-title":"Ces Slov Oftalmol"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archopht.1987.01060060049030","article-title":"Selection of Iodine 125 for the collaborative ocular melanoma study","volume":"105","author":"Earle","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"474","DOI":"10.11622\/smedj.2019054","article-title":"Clinical spectrum, treatment and outcomes of uveal melanoma in a tertiary care centre","volume":"60","author":"Wong","year":"2019","journal-title":"Singapore Med J"},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.apradiso.2005.08.011","article-title":"Studies on the production and quality assurance of miniature (125) I radioactive sources suitable for treatment of ocular and prostate cancers","volume":"64","author":"Saxena","year":"2006","journal-title":"Appl Radiat Isot"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2014.5395","article-title":"International validation of the American Joint Committee on Cancer's 7th edition classification of uveal melanoma","volume":"133","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R10-20260508","first-page":"41","article-title":"Clinical and histopathological characteristics of uveal melanoma in Asian Indians. A study of 103 patients","volume":"52","author":"Biswas","year":"2004","journal-title":"Indian J Ophthalmol"},{"key":"R11-20260508","first-page":"21","article-title":"Indigenous 125I brachytherapy source for the management of intraocular melanomas in India","volume":"28","author":"Shah","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"612.e1","DOI":"10.1016\/j.ajo.2005.05.034","article-title":"Population-based incidence of uveal melanoma in various races and ethnic groups","volume":"140","author":"Hu","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1148\/radiology.169.1.3420267","article-title":"Choroidal melanoma: I-125 plaque therapy","volume":"169","author":"Bosworth","year":"1988","journal-title":"Radiology"},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2018.01.032","article-title":"Clinical predictors of regression of choroidal melanoma after brachytherapy. A growth curve model","volume":"125","author":"Rashid","year":"2018","journal-title":"Ophthalmology"},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.ophtha.2017.04.013","article-title":"Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma","volume":"124","author":"Mruthyunjaya","year":"2017","journal-title":"Ophthalmology"},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/j.ophtha.2020.01.032","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19","volume":"127","author":"Jampol","year":"2020","journal-title":"Ophthalmology"},{"key":"R17-20260508","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/0301-4738.128618","article-title":"Brachytherapy of intraocular tumors using BARC I-125 Ocu-Prosta seeds","volume":"62","author":"Khetan","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2008.10.013","article-title":"I-125 Brachytherapy for choroidal melanoma: Photographic and angiographic abnormalities. Collaborative Ocular Melanoma Study. COMS Report No. 30","volume":"116","author":"Boldt","year":"2009","journal-title":"Ophthalmology"},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","article-title":"Personalised prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8 year period: The 2017 Harry S Gradle lecture","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.3390\/app10228081","article-title":"Histopathology and genetic biomarkers of choroidal melanoma","volume":"10","author":"Broggi","year":"2020","journal-title":"Appl Sci"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1694_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:54:39Z","timestamp":1787763279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1694_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":20,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1694_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"2023-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}